Martin Tolar

CoMentis, Inc. focuses on developing drugs to treat various central nervous system disorders. Its research and development spectrum include BACE inhibitors and modulators of the a7 nicotinic acetylcholine receptor (NAChR). The company was founded by John P. Cooke and Muralitharan Kengatharan in 2006 and is headquartered in South San Francisco, CA.

NormOxys, Inc. develops small-molecule therapeutics for the treatment of cancer. Its major product is OXY111A. The company was founded by Conrad J Bletzer, Jr. Claude Nicoalu, Jean-Mearie Lehn, Gay Goodman, Ruth Greferath and Roscoe Brady in 2004 and is headquartered in Brighton, MA.

BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

Tafkak, Inc. provides genome sequencing and analysis solutions. It offers tools and solutions to researchers, drug developers and clinicians determine the genetic basis of human disease and drug response. The firm provides knomeCLINIC a software suite that helps medical researchers and clinicians interpret human genomes for biological relevance; kGAP a cloud-enabled genome informatics engine that automates the process of standardizing, distilling, annotating and comparing sequence data. It also offers knomeVARIANTS, a discovery-supportive interpretation tool, which helps researchers to find causal variants and genes. The company was founded by Jorge Conde and George M. Church in 2007 and is headquartered in Waltham, MA.

Alzheon, Inc. engages in the provision of medical development. It specializes in treatment for brain health, memory, and aging. It offers ALZ-801, an oral small molecule inhibitor of amyloid formation and neurotoxicity with potential to be a therapy for a genetically defined population of patients with or at high risk for Alzheimer's disease and other neurodegenerative disorders. The company was founded by Martin Tolar in June 2013 and is headquartered in Framingham, MA.